ERBB2 and non-small cell lung carcinoma: Targeting HER2 by various inhibitors such as pyrotinib, poziotinib, lapatinib afatinib, dacomitinib, and neratinib has been studied as a therapeutic option in patients with NSCLC, but unhopefully, none of them could yet get approved [173–176].